Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 9/2023

21-01-2023 | Prostate Cancer | Review

Nanobodies: a new potential for prostate cancer treatment

Authors: Jianfei Su, Xiaodi Liu, Shanqi Guo, Jingxian Zhang, Xueqin Wei, Xiaojiang Li

Published in: Journal of Cancer Research and Clinical Oncology | Issue 9/2023

Login to get access

Abstract

Background

The current progressive increase in the cancer burden of prostate cancer requires the exploration of new diagnostic and therapeutic approaches. Nanobodies are single-domain antibodies with the advantages of small size, high stability, easy processing and modification, which are increasingly used in the treatment of many types of cancer.

Methods

This review analyzed the relevant literature in PubMed and other databases.

Result

In the retrieved literature, nanobodies are widely used in the treatment of prostate cancer. The preparation of nanobodies targeting PSA or PSMA is straightforward. For diagnostic purposes, nanobodies can be used in the preparation of biosensors for more sensitive identification of prostate cancer; for therapeutic purposes, nanobodies are used in the preparation of immunotoxic and ADC drugs. Preclinical in vivo and in vitro experiments have shown that this therapeutic approach is feasible. This article is a review of the above to provide new ideas for the treatment of prostate cancer.

Conclusion

Compared with traditional antibodies, nano-antibodies have the advantages of small size, high stability, and high penetration. These advantages make nano-antibodies worthy to be widely used. Current studies have shown that nanobodies have advantages and future in the diagnosis and treatment of prostate cancer.
Literature
go back to reference Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA (2016) The 2014 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 40(2):244–252CrossRefPubMed Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA (2016) The 2014 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 40(2):244–252CrossRefPubMed
go back to reference Pleschberger M, Saerens D, Weigert S, Sleytr UB, Muyldermans S, Sara M, Egelseer EM (2004) An S-layer heavy chain camel antibody fusion protein for generation of a nanopatterned sensing layer to detect the prostate-specific antigen by surface plasmon resonance technology. Bioconjug Chem 15:664–671. https://doi.org/10.1021/bc049964wCrossRefPubMed Pleschberger M, Saerens D, Weigert S, Sleytr UB, Muyldermans S, Sara M, Egelseer EM (2004) An S-layer heavy chain camel antibody fusion protein for generation of a nanopatterned sensing layer to detect the prostate-specific antigen by surface plasmon resonance technology. Bioconjug Chem 15:664–671. https://​doi.​org/​10.​1021/​bc049964wCrossRefPubMed
go back to reference Yi-kai B, Hao-fei H, Jie S, Zhi-fang Z, Zhi-meng W (2022) Development and biological activity analysis of PSMA specific multivalent nanobodies China. Biotechnology 42:37–45 Yi-kai B, Hao-fei H, Jie S, Zhi-fang Z, Zhi-meng W (2022) Development and biological activity analysis of PSMA specific multivalent nanobodies China. Biotechnology 42:37–45
Metadata
Title
Nanobodies: a new potential for prostate cancer treatment
Authors
Jianfei Su
Xiaodi Liu
Shanqi Guo
Jingxian Zhang
Xueqin Wei
Xiaojiang Li
Publication date
21-01-2023
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 9/2023
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-022-04515-y

Other articles of this Issue 9/2023

Journal of Cancer Research and Clinical Oncology 9/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare